Vicore Pharma Holding AB (DE:6Y4)
FRANKFURT:6Y4
Want to see DE:6Y4 full AI Analyst Report?
6Y4 Stock Chart & Stats
€0.92
€0.08(9.48%)
At close: 4:00 PM EST
€0.92
€0.08(9.48%)
Day’s Range― - ―
52-Week Range€0.64 - €1.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€282.18M
Enterprise Value€2.47B
Total Cash (Recent Filing)€1.06B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 21, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.49Price Target Upside279.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€741.25K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero reported debt and materially expanded equity significantly improve financial flexibility and reduce refinancing and interest-rate risk. This durable balance-sheet strength supports sustained investment in clinical programs and acts as a buffer to extend operational runway absent immediate commercial cash flow.
Focused Clinical Pipeline (AT2R / IPF)A concentrated clinical-stage pipeline focused on AT2R and idiopathic pulmonary fibrosis targets a large unmet respiratory market. The defined mechanistic focus and clear lead candidates increase development efficiency and create identifiable binary clinical milestones that can materially de-risk and drive long-term value if successful.
Lean Operating StructureA 33-person workforce implies a lean operating model well-aligned with a clinical-stage biotech, helping to limit fixed overhead and stretch capital. Structural cost discipline can extend cash runway per financing round and prioritize R&D spend toward high-impact clinical activities over administrative expansion.
Bears Say
Persistent Cash BurnOperating cash flow has been negative in each year and deteriorated materially in 2025, representing a persistent structural cash burn. That ongoing outflow forces reliance on external financing, raises dilution risk over time and constrains the company’s ability to fund multiple clinical programs or respond to trial setbacks without new capital.
Revenue Volatility And DeclineRevenue exhibited high volatility and a steep ~51% decline in 2025, undermining the predictability of organic funding sources. For a clinical-stage developer, such collapses reduce visibility into financing needs, complicate planning and suggest revenue is not a stable long-term buffer for funding R&D activities.
Deep And Worsening LossesProfitability is structurally negative with very large net losses relative to revenue and consistently negative returns on equity. Sustained heavy losses will require repeated external capital, increase dilution, and limit shareholder returns unless clinical milestones are achieved that materially alter the revenue or partnership profile.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.64 and its highest was €1.18 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €282.18M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 90 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -€0.036 earnings per share for the quarter, beating the consensus estimate of -€0.044 by €0.008.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.036 in its last earnings report, beating expectations of -€0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
6Y4 Stock 12 Month Forecast
Average Price Target
€3.49
▲(279.81% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---